BIOT
EquitiesGlobalThematicAccumulating
L&G Pharma Breakthrough UCITS ETF
It tracks the Solactive Pharma Breakthrough Value index with 36 companies developing drugs for rare diseases. Almost the entire portfolio sits in the healthcare sector.
Key facts
- ISIN
- IE00BF0H7608
- Provider
- L&G
- Index
- Solactive Pharma Breakthrough Value
- TER (annual cost)
- 0.49%
- Replication
- Physical (full)
- Distributions
- Accumulating
- Domicile
- Ireland
- Base currency
- USD
- Launch year
- 2018
- Fund size (approx.)
- ~€<0.1bn
Listings
| Exchange | Ticker |
|---|---|
| Xetra | ETLI |
| gettex | ETLI |
| Euronext Amsterdam | BIOT |
| Borsa Italiana | BIOT |
| London Stock Exchange | BIOT |
| SIX Swiss Exchange | BIOT |
Related articles from the blog
Dollar Cost Averaging (DCA)ETFs
What are thematic ETFs and are they worth having in your portfolio?
From AI and clean energy to biotechnology: investing in trends or a hype trap?
16 min read
Dollar Cost Averaging (DCA)ETFs
How to build a resilient portfolio
A guide for investors who want to build something stable, simple and rewarding over the long term.
19 min read
Dollar Cost Averaging (DCA)ETFs
What is an ETF? The complete beginner's guide
Learn how ETFs work, why they have become so popular and how you can use them to invest with strategy.
22 min read
Data as of 2026-08. Refreshed periodically. This content is for information only and is not investment advice or a recommendation. Verify the official documents (KID/prospectus) with the provider before any decision.